Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis.
Budget impact analysis
Dapagliflozin
General Practitioners
Italy
Journal
Acta diabetologica
ISSN: 1432-5233
Titre abrégé: Acta Diabetol
Pays: Germany
ID NLM: 9200299
Informations de publication
Date de publication:
18 Apr 2024
18 Apr 2024
Historique:
received:
28
12
2023
accepted:
19
03
2024
medline:
18
4
2024
pubmed:
18
4
2024
entrez:
18
4
2024
Statut:
aheadofprint
Résumé
In 2022, in Italy, general practitioners (GPs) have been allowed to prescribe SGLT2i in Type 2 Diabetes (T2D) under National Health Service (NHS) reimbursement. In the pivotal clinical trial named DECLARE-TIMI 58, dapagliflozin reduced the risk of hospitalization for heart failure, CV death and kidney disease progression compared to placebo in a population of T2D patients. This study evaluated the health and economic impact of dapagliflozin for T2D patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian GPs setting. A budget impact model was developed to assess the health and economic impact of introducing dapagliflozin in GPs setting. The analysis was conducted by adopting the Italian NHS perspective and a 3-year time horizon. The model estimated and compared the health outcomes and direct medical costs associated with a scenario with dapagliflozin and other antidiabetic therapies available for GPs prescription (scenario B) and a scenario where only other antidiabetic therapies are available (scenario A). Rates of occurrence of cardiovascular and renal complications as well as adverse events were captured from DECLARE-TIMI 58 trial and the literature, while cost data were retrieved from the Italian tariff and the literature. One-way sensitivity analyses were conducted to test the impact of model parameters on the budget impact. The model estimated around 442.000 patients eligible for the treatment with dapagliflozin in the GPs setting for each simulated year. The scenario B compared to scenario A was associated with a reduction in the occurrence of cardiovascular and renal complication (-1.83%) over the 3 years simulated. Furthermore, the scenario A allowed for an overall cost saving of 102,692,305€: 14,521,464€ in the first year, 33,007,064€ in the second and 55,163,777€ in the third. The cost of cost of drug acquisition, the probability of cardiovascular events and the percentage of patients potentially eligible to the treatment were the factor with largest impact on the results. The use of dapagliflozin in GPs setting reduce the number of CVD events, kidney disease progression and healthcare costs in Italy. These data should be considered to optimize the value produced for the T2D patients who had or were at risk for atherosclerotic cardiovascular disease.
Identifiants
pubmed: 38634912
doi: 10.1007/s00592-024-02276-3
pii: 10.1007/s00592-024-02276-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : AstraZeneca
ID : No number
Informations de copyright
© 2024. The Author(s).
Références
Kahn SE, Cooper ME, Del Prato S (2014) Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383:1068–1083. https://doi.org/10.1016/S0140-6736(13)62154-6
doi: 10.1016/S0140-6736(13)62154-6
pubmed: 24315620
Tinajero MG, Malik VS (2021) An update on the epidemiology of type 2 diabetes: a global perspective. Endocrinol Metab Clin North Am 50:337–355. https://doi.org/10.1016/j.ecl.2021.05.013
doi: 10.1016/j.ecl.2021.05.013
pubmed: 34399949
Khan A, Shang N, Nestor JG et al (2023) Polygenic risk affects the penetrance of monogenic kidney disease. Medrxiv. https://doi.org/10.1101/2023.05.07.23289614
doi: 10.1101/2023.05.07.23289614
pubmed: 38045321
pmcid: 10690356
Kharroubi AT, Darwish HM (2015) Diabetes mellitus: the epidemic of the century. World J Diabetes 6:850–867. https://doi.org/10.4239/wjd.v6.i6.850
doi: 10.4239/wjd.v6.i6.850
pubmed: 26131326
pmcid: 4478580
Onyango EM, Onyango BM (2018) The rise of noncommunicable diseases in Kenya: an examination of the time trends and contribution of the changes in diet and physical inactivity. J Epidemiol Glob Health 8:1–7. https://doi.org/10.2991/j.jegh.2017.11.004
doi: 10.2991/j.jegh.2017.11.004
pubmed: 30859780
pmcid: 7325816
Ramtahal R, Khan C, Maharaj-Khan K et al (2015) Prevalence of self-reported sleep duration and sleep habits in type 2 diabetes patients in South Trinidad. J Epidemiol Glob Health 5:S35-43. https://doi.org/10.1016/j.jegh.2015.05.003
doi: 10.1016/j.jegh.2015.05.003
pubmed: 26073574
pmcid: 4666733
American Diabetes Association (2018) 4. lifestyle management: standards of medical care in diabetes-2018. Diabetes Care 41:S38–S50. https://doi.org/10.2337/dc18-S004
doi: 10.2337/dc18-S004
Bahia LR, Araujo DV, Schaan BD et al (2011) The costs of type 2 diabetes mellitus outpatient care in the Brazilian public health system. Value Health 14:S137-140. https://doi.org/10.1016/j.jval.2011.05.009
doi: 10.1016/j.jval.2011.05.009
pubmed: 21839888
Ferreira R, Colugnati F (2021) Monitoring chronic kidney disease evolution using frailty models. Int J Epidemiol 50:i51–i52. https://doi.org/10.1093/ije/dyab168.139
doi: 10.1093/ije/dyab168.139
Sharma A, Mittal S, Aggarwal R, Chauhan MK (2020) Diabetes and cardiovascular disease: inter-relation of risk factors and treatment. Future J Pharm Sci 6:130. https://doi.org/10.1186/s43094-020-00151-w
doi: 10.1186/s43094-020-00151-w
Russo GT, Baggio G, Rossi MC, Kautzky-Willer A (2015) Type 2 diabetes and cardiovascular risk in women. Int J Endocrinol 2015:832484. https://doi.org/10.1155/2015/832484
doi: 10.1155/2015/832484
pubmed: 25883650
pmcid: 4391524
Schmidt AM (2019) Diabetes mellitus and cardiovascular disease. Arterioscler Thromb Vasc Biol 39:558–568. https://doi.org/10.1161/ATVBAHA.119.310961
doi: 10.1161/ATVBAHA.119.310961
pubmed: 30786741
pmcid: 6532416
Cannon CP, McGuire DK, Pratley R et al (2018) Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and safety cardiovascular outcomes trial (vertis-CV). Am Heart J 206:11–23. https://doi.org/10.1016/j.ahj.2018.08.016
doi: 10.1016/j.ahj.2018.08.016
pubmed: 30290289
Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657. https://doi.org/10.1056/NEJMoa1611925
doi: 10.1056/NEJMoa1611925
pubmed: 28605608
Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128. https://doi.org/10.1056/NEJMoa1504720
doi: 10.1056/NEJMoa1504720
pubmed: 26378978
Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347–357. https://doi.org/10.1056/NEJMoa1812389
doi: 10.1056/NEJMoa1812389
pubmed: 30415602
Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393:31–39. https://doi.org/10.1016/S0140-6736(18)32590-X
doi: 10.1016/S0140-6736(18)32590-X
pubmed: 30424892
Marx N, Federici M, Schütt K et al (2023) 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 44:4043–4140. https://doi.org/10.1093/eurheartj/ehad192
doi: 10.1093/eurheartj/ehad192
pubmed: 37622663
Rossing P, Caramori ML, Chan JCN et al (2022) Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence. Kidney Int 102:990–999. https://doi.org/10.1016/j.kint.2022.06.013
doi: 10.1016/j.kint.2022.06.013
pubmed: 36272755
American Diabetes Association Professional Practice Committee (2024) Summary of revisions: standards of care in diabetes-2024. Diabetes Care 47:S5–S10. https://doi.org/10.2337/dc24-SREV
doi: 10.2337/dc24-SREV
Birkeland KI, Jørgensen ME, Carstensen B et al (2017) Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol 5:709–717. https://doi.org/10.1016/S2213-8587(17)30258-9
doi: 10.1016/S2213-8587(17)30258-9
pubmed: 28781064
Norhammar A, Bodegård J, Nyström T et al (2019) Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the declare-TIMI 58 trial: a nationwide observational study. Diabetes Obes Metab 21:1136–1145. https://doi.org/10.1111/dom.13627
doi: 10.1111/dom.13627
pubmed: 30609272
pmcid: 6593417
Persson F, Nyström T, Jørgensen ME et al (2018) Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study. Diabetes Obes Metab 20:344–351. https://doi.org/10.1111/dom.13077
doi: 10.1111/dom.13077
pubmed: 28771923
Furtado RHM, Bonaca MP, Raz I et al (2019) Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction. Circulation 139:2516–2527. https://doi.org/10.1161/CIRCULATIONAHA.119.039996
doi: 10.1161/CIRCULATIONAHA.119.039996
pubmed: 30882239
Kato ET, Silverman MG, Mosenzon O et al (2019) Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 139:2528–2536. https://doi.org/10.1161/CIRCULATIONAHA.119.040130
doi: 10.1161/CIRCULATIONAHA.119.040130
pubmed: 30882238
Viswanathan V, Singh KP (2019) Use of dapagliflozin in the management of type 2 diabetes mellitus: a real-world evidence study in Indian patients (forefront). Diabetes Technol Ther 21:415–422. https://doi.org/10.1089/dia.2019.0052
doi: 10.1089/dia.2019.0052
pubmed: 31339784
Sethi B, Sahay R, Tiwaskar M et al (2023) Effectiveness of dapagliflozin as add-on to metformin with or without other oral antidiabetic drugs in type 2 diabetes mellitus: a multicentre, retrospective, real-world database study. Drugs Real World Outcomes. https://doi.org/10.1007/s40801-023-00398-8
doi: 10.1007/s40801-023-00398-8
pubmed: 37898577
pmcid: 10928049
Fadini GP, Morales C, Caballero I et al (2022) Efficacy of dapagliflozin in southern Europe across the spectrum of characteristics of type 2 diabetes: an international real-world analysis. Diabetes Metab Syndr Obes 15:3533–3541. https://doi.org/10.2147/DMSO.S390075
doi: 10.2147/DMSO.S390075
pubmed: 36411790
pmcid: 9675331
McEwan P, Morgan AR, Boyce R et al (2021) The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: an economic evaluation using data from the declare-TIMI 58 trial. Diabetes Obes Metab 23:1020–1029. https://doi.org/10.1111/dom.14308
doi: 10.1111/dom.14308
pubmed: 33368855
pmcid: 8048502
Parizo JT, Goldhaber-Fiebert JD, Salomon JA et al (2021) Cost-effectiveness of dapagliflozin for treatment of patients with heart failure with reduced ejection fraction. JAMA Cardiol 6:926–935. https://doi.org/10.1001/jamacardio.2021.1437
doi: 10.1001/jamacardio.2021.1437
pubmed: 34037681
Rane A, Nechi RN, Imam M et al (2023) Comparative value of dapagliflozin vs empagliflozin in patients with heart failure and preserved ejection fraction: a cost-effectiveness analysis. J Manag Care Spec Pharm 29:1045–1053. https://doi.org/10.18553/jmcp.2023.29.9.1045
doi: 10.18553/jmcp.2023.29.9.1045
pubmed: 37610112
pmcid: 10508839
Nechi RN, Rane A, Karaye RM et al (2023) Cost-effectiveness of dapagliflozin vs empagliflozin for treating heart failure with reduced ejection fraction in the United States. Clin Ther 45:627–632. https://doi.org/10.1016/j.clinthera.2023.05.002
doi: 10.1016/j.clinthera.2023.05.002
pubmed: 37270374
Isaza N, Calvachi P, Raber I et al (2021) Cost-effectiveness of dapagliflozin for the treatment of heart failure with reduced ejection fraction. JAMA Netw Open 4:e2114501. https://doi.org/10.1001/jamanetworkopen.2021.14501
doi: 10.1001/jamanetworkopen.2021.14501
pubmed: 34313742
pmcid: 8317009
Nguyen B-N, Mital S, Bugden S, Nguyen HV (2023) Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction. Int J Cardiol 376:83–89. https://doi.org/10.1016/j.ijcard.2023.01.080
doi: 10.1016/j.ijcard.2023.01.080
pubmed: 36736672
Briggs AH, Weinstein MC, Fenwick EAL et al (2012) Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group-6. Med Decis Making 32:722–732. https://doi.org/10.1177/0272989X12458348
doi: 10.1177/0272989X12458348
pubmed: 22990087
Salute della M, Relazione al Parlamento (2021) sullo stato delle conoscenze e delle nuove acquisizioni in tema di diabete mellito - Legge 16 marzo 1987, n. 115, recante Disposizioni per la prevenzione e la cura del diabete mellito
Istituto Nazionale di Statistica - Demo ISTAT
Blak BT, Thompson M, Dattani H, Bourke A (2011) Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care 19:251–255. https://doi.org/10.14236/jhi.v19i4.820
doi: 10.14236/jhi.v19i4.820
pubmed: 22828580
Schrag A, Horsfall L, Walters K et al (2015) Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol 14:57–64. https://doi.org/10.1016/S1474-4422(14)70287-X
doi: 10.1016/S1474-4422(14)70287-X
pubmed: 25435387
Bonora E (2022) La pandemia diabete in Italia. L’ndocrinologo 23:337–344. https://doi.org/10.1007/s40619-022-01130-4
doi: 10.1007/s40619-022-01130-4
Cura Del Diabete E Mmg: un attore chiave del processo di cura con le armi spuntate. In: Motoresanità.it. https://motoresanita.it/eventi/cura-del-diabete-e-mmg-un-attore-chiave-del-processo-di-cura-con-le-armi-spuntate/ . Accessed 28 Dec 2023
The Health Improvement Network (THIN). THIN data on file
Italian Medicine Agency (AIFA) Nota 100. URL: https://www.aifa.gov.it/en/nota-100
Agenzia Italiana del Farmaco (AIFA). URL: https://www.aifa.gov.it/
Gazzetta Ufficiale della Repubblica Italiana - n. 17 21/1/2023. URL: https://www.gazzettaufficiale.it/eli/gu/2023/01/21/17/sg/pdf
Gazzetta Ufficiale della Republica Italiana - n. 213 06/09/2021. URL: https://www.gazzettaufficiale.it/gazzetta/serie_generale/caricaDettaglio?dataPubblicazioneGazzetta=2021-09-06&numeroGazzetta=213
Gazzetta Ufficiale della Repubblica Italiana - n. 249 23/10/2019. URL: https://www.gazzettaufficiale.it/eli/gu/2019/10/23/249/sg/pdf
Gazzetta ufficiale della Repubblica Italiana - n. 53 04/03/2022. URL: https://www.gazzettaufficiale.it/eli/gu/2022/03/04/53/sg/pdf
Gazzetta Ufficiale della Repubblica Italiana - n. 179 28/7/2021. URL: https://www.gazzettaufficiale.it/eli/gu/2021/07/28/179/sg/pdf
Gazzetta Ufficiale della Repubblica Italiana - n. 201 30/8/2014. URL: https://www.gazzettaufficiale.it/gazzetta/serie_generale/caricaDettaglio?dataPubblicazioneGazzetta=2014-08-30&numeroGazzetta=201
Gazzetta ufficiale della Repubblica Italiana - n. 273 21/11/2013. URL: https://www.gazzettaufficiale.it/eli/gu/2013/11/21/273/sg/pdf
Gazzetta Ufficiale della Repubblica Italiana - n. 240 13/10/2016. URL: https://www.gazzettaufficiale.it/eli/gu/2022/10/13/240/sg/pdf
Gazzetta Ufficiale della Repubblica Italiana - n. 246 22/10/2018. URL: https://www.gazzettaufficiale.it/eli/gu/2018/10/22/246/sg/pdf
D’Angiolella LS, Cortesi PA, Pitotti C et al (2017) Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context. Eur J Heart Fail 19:1551–1553. https://doi.org/10.1002/ejhf.919
doi: 10.1002/ejhf.919
pubmed: 28849615
Mantovani LG, Fornari C, Madotto F et al (2011) Burden of acute myocardial infarction. Int J Cardiol 150:111–112. https://doi.org/10.1016/j.ijcard.2011.04.030
doi: 10.1016/j.ijcard.2011.04.030
pubmed: 21605921
Lucchese M, Borisenko O, Mantovani LG et al (2017) Cost-utility analysis of bariatric surgery in Italy: results of decision-analytic modelling. Obes Facts 10:261–272. https://doi.org/10.1159/000475842
doi: 10.1159/000475842
pubmed: 28601866
pmcid: 5644931
Turchetti G, Bellelli S, Amato M et al (2017) The social cost of chronic kidney disease in Italy. Eur J Health Econ 18:847–858. https://doi.org/10.1007/s10198-016-0830-1
doi: 10.1007/s10198-016-0830-1
pubmed: 27699568
Cicchetti A, Ruggeri M, Codella P, Ridolfi A (2011) I costi socio-sanitari dell’insufficienza renale cronica. Farmeconomia E Percorsi Terapeutici 12:75–82
Palmer SC, Tendal B, Mustafa RA et al (2021) Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 372:m4573. https://doi.org/10.1136/bmj.m4573
doi: 10.1136/bmj.m4573
pubmed: 33441402
pmcid: 7804890
Reifsnider OS, Kansal A, Wanner C et al (2019) SAT-296 Cost-effectiveness analysis of empagliflozin treatment in patients with type 2 diabetes and chronic kidney disease based on subgroup of EMPA-reg outcomE. Kidney Intl Rep 4:S132. https://doi.org/10.1016/j.ekir.2019.05.336
doi: 10.1016/j.ekir.2019.05.336
Parekh W, Streeton SE, Baker-Knight J et al (2018) The economic burden of insulin-related hypoglycemia in adults with diabetes: an analysis from the perspective of the Italian healthcare system. Diabetes Ther 9:1037–1047. https://doi.org/10.1007/s13300-018-0418-0
doi: 10.1007/s13300-018-0418-0
pubmed: 29600505
pmcid: 5984921
Haldrup S, Lapolla A, Gundgaard J, Wolden ML (2020) Cost-effectiveness of switching to insulin degludec from other basal insulins in real-world clinical practice in Italy. J Med Econ 23:271–279. https://doi.org/10.1080/13696998.2019.1669613
doi: 10.1080/13696998.2019.1669613
pubmed: 31526202
Ministero della Salute Gazzetta Ufficiale (2013) Supplemento ordinario alla Gazzetta Ufficiale„ n. 23 del 28 gennaio 2013 - Serie generale. DECRETO 18 ottobre 2012. Remunerazione delle prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale
Nelson AJ, Pagidipati NJ, Aroda VR et al (2021) Incorporating SGLT2i and GLP-1RA for cardiovascular and kidney disease risk reduction: call for action to the cardiology community. Circulation 144:74–84. https://doi.org/10.1161/CIRCULATIONAHA.121.053766
doi: 10.1161/CIRCULATIONAHA.121.053766
pubmed: 34228476
McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008. https://doi.org/10.1056/NEJMoa1911303
doi: 10.1056/NEJMoa1911303
pubmed: 31535829
Heerspink HJL, Sjöström CD, Jongs N et al (2021) Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. Eur Heart J 42:1216–1227. https://doi.org/10.1093/eurheartj/ehab094
doi: 10.1093/eurheartj/ehab094
pubmed: 33792669
pmcid: 8244648
McEwan P, Bennett H, Khunti K et al (2020) Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence. Diabetes Obes Metab 22:2364–2374. https://doi.org/10.1111/dom.14162
doi: 10.1111/dom.14162
pubmed: 32744392
van Schoonhoven AV, Schöttler MH, Serné EH et al (2023) The health and budget impact of sodium-glucose co-transporter-2 inhibitors (SGLT2is) in The Netherlands. J Med Econ 26:547–553. https://doi.org/10.1080/13696998.2023.2194802
doi: 10.1080/13696998.2023.2194802
pubmed: 36987694
IS (2016) Budget impact analysis of empagliflozin for the treatment of type 2 diabetes in Italy. Farmeconomia Health Econ Ther Pathw 17:19–27
doi: 10.7175/fe.v17i1.1238
Catharina de Beer J, Snyman J, Ker J et al (2023) Budget impact analysis of empagliflozin in the treatment of patients with type 2 diabetes with established cardiovascular disease in South Africa. Value Health Reg Issues 33:91–98. https://doi.org/10.1016/j.vhri.2022.08.012
doi: 10.1016/j.vhri.2022.08.012
pubmed: 36327769
Voorhaar M, Nurkanovic L, Ustyugova AV et al (2018) PDB39 - empagliflozin for patients in the Netherlands with type 2 diabetes mellitus and established cardiovascular disease: a budget impact model. Value in Health 21:S124. https://doi.org/10.1016/j.jval.2018.09.745
doi: 10.1016/j.jval.2018.09.745
Impact of Empagliflozin (Jardiance) to the NHS- estimation of budget and event impact based on EMPA-reg outcome data. In: ISPOR | International Society For Pharmacoeconomics and Outcomes Research. https://www.ispor.org/publications/journals/value-in-health/abstract/Volume-19--Issue-7/Impact-of-Empagliflozin-(Jardiance)-to-the-NHS--Estimation-of-Budget-and-Event-Impact-Based-on-Empa-Reg-Outcome-Data . Accessed 28 Dec 2023
Agenzia Italiana del Farmaco (AIFA) Valutazioni economiche. URL: https://www.aifa.gov.it/valutazioni-economiche
Rahman H, Khan SU, Lone AN et al (2023) Sodium-glucose cotransporter-2 inhibitors and primary prevention of atherosclerotic cardiovascular disease: a meta-analysis of randomized trials and systematic review. J Am Heart Assoc 12:e030578. https://doi.org/10.1161/JAHA.123.030578
doi: 10.1161/JAHA.123.030578
pubmed: 37581396
pmcid: 10492958
Avgerinos I, Karagiannis T, Matthews DR et al (2023) Effects of sodium-glucose co-transporter-2 inhibitors by background cardiovascular medications: a systematic review and meta-analysis. Diabetes Obes Metab 25:3020–3029. https://doi.org/10.1111/dom.15200
doi: 10.1111/dom.15200
pubmed: 37435776
Wahinya M, Khan Z (2023) Sodium-glucose cotransporter-2 (SGLT2) inhibitor therapy for the primary and secondary prevention of heart failure in patients with and without type 2 diabetes mellitus: a systematic review. Cureus 15:e37388. https://doi.org/10.7759/cureus.37388
doi: 10.7759/cureus.37388
pubmed: 37181972
pmcid: 10171706
Lavie CJ, Milani RV, Ventura HO (2009) Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 53:1925–1932. https://doi.org/10.1016/j.jacc.2008.12.068
doi: 10.1016/j.jacc.2008.12.068
pubmed: 19460605
Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403. https://doi.org/10.1056/NEJMoa012512
doi: 10.1056/NEJMoa012512
pubmed: 11832527